- Conditions
- Childhood-Onset Fluency Disorder (Stuttering)
- Interventions
- Ecopipam, Placebo
- Drug
- Lead sponsor
- Emalex Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 9
- States / cities
- Riverside, California • Santa Ana, California • Jacksonville, Florida + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Childhood-Onset Fluency Disorder
- Interventions
- NOE-105, Placebo
- Drug
- Lead sponsor
- Noema Pharma AG
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 6
- States / cities
- Bellflower, California • Jacksonville, Florida • Orlando, Florida + 3 more
- Conditions
- Stuttering, Adult, Childhood-onset Fluency Disorder, Speech Disorders, Language Disorders, Communication Disorder
- Interventions
- Ecopipam 50mg, Ecopipam 100mg
- Drug
- Lead sponsor
- Gerald Maguire, MD
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Riverside, California